Elizabeth Won

Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer

Luis A. Rojas, Zachary Sethna, Kevin C. Soares et al. · Nature · 2023 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +17

First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial

Yelena Y. Janjigian, Steven B. Maron, Walid K. Chatila et al. · The Lancet Oncology · 2020 · 357 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo et al. · The Lancet Oncology · 2019 · 284 citations · Full text

Medicine, Oncology, Pharmacology +13

RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer

Zachary Sethna, Pablo Guasp, Charlotte Reiche et al. · Nature · 2025 · 232 citations · Full text

Medicine, Immunology, Oncology +12

First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA).

Yelena Y. Janjigian, Joanne F. Chou, Marc Simmons et al. · Journal of Clinical Oncology · 2019 · 48 citations

Medicine, Oncology, Pharmacology +17